October 16, 2024 17:00 Non Regulatory Flerie AB’s Nomination Committee for the 2025 Annual General Meeting
October 11, 2024 08:00 Non Regulatory Invitation to presentation and Q&A of Flerie’s Q3 2024 interim report
July 29, 2024 12:42 Non Regulatory Flerie increases its shareholding in Xspray Pharma and comments on FDA feedback on Dasynoc
July 12, 2024 08:00 Non Regulatory Invitation to presentation and Q&A of Flerie’s Q2 2024 interim report
June 26, 2024 16:15 Regulatory Flerie has been approved for listing on Nasdaq Stockholm and publishes its prospectus
June 13, 2024 20:35 Regulatory Flerie carries out a directed share issue of more than SEK 600 million
June 11, 2024 08:00 Regulatory Flerie explores the conditions for carrying out a directed issue of ordinary shares of up to approximately SEK 600 million of which approximately SEK 520 million is pre-committed
June 7, 2024 Regulatory InDex Pharmaceuticals has received a conditional approval for continued listing on Nasdaq First North Growth Market after the reverse merger of Flerie
May 27, 2024 Regulatory InDex Pharmaceuticals publishes company description in connection with the reverse merger of Flerie
May 20, 2024 Regulatory InDex Pharmaceuticals has entered into a conditional agreement regarding a reverse merger with Flerie
March 1, 2024 Flerie Invest AB has increased its holding in Lipum AB (publ), whereby the limit for mandatory bidding has been exceeded
February 6, 2023 09:40 Non Regulatory Flerie appoints seasoned industry experts to its Board of Directors
October 15, 2021 07:00 Non Regulatory Flerie Invest AB leads $52m acquisition of Swedish Biopharma Facility from Charles River